Seer Reports First Quarter 2024 Financial Results
Seer Reports First Quarter 2024 Financial Results
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications
通过越来越多的客户演示和出版物展示了Proteograph产品套件的强大功能
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024.
加利福尼亚州雷德伍德城，2024年5月8日（环球新闻专线）——将颠覆性蛋白质组学新平台商业化的领先生命科学公司Seer, Inc.（纳斯达克股票代码：SEER）今天公布了截至2024年3月31日的第一季度财务业绩。
Recent Highlights
近期亮点
- Achieved revenue of $3.1 million for the first quarter of 2024
- Announced the expansion of the Seer Technology Access Center (STAC) program to Europe, providing researchers with end-to-end services from sample to data
- Further validated the power of the Proteograph Product Suite with three peer-reviewed publications in leading journals since the beginning of the year, with additional manuscripts available on pre-print servers
- Launched the 2024 Seer Insights Grant Program to enable interesting studies and applications of the Proteograph Product Suite, further increasing the accessibility of deep, unbiased proteomic data at scale
- Authorized an open-market share repurchase program of up to $25 million
- Ended the quarter with $359.2 million of cash, cash equivalents and investments
- 2024年第一季度实现收入310万美元
- 宣布将Seer技术访问中心（STAC）计划扩展到欧洲，为研究人员提供从样本到数据的端到端服务
- 自年初以来，在领先期刊上发表了三篇经过同行评审的出版物，进一步验证了Proteograph产品套件的强大功能，预印服务器上还有其他手稿
- 启动了 2024 年 Seer Insights 资助计划，以支持 Proteograph 产品套件的有趣研究和应用，进一步提高大规模获得深度、无偏见的蛋白质组数据的可访问性
- 批准了一项高达2500万美元的公开市场股票回购计划
- 本季度末拥有3.592亿美元的现金、现金等价物和投资
"We are committed to reducing barriers to the commercial adoption of our differentiated technology, despite experiencing continued headwinds in the quarter. We are taking every action to increase accessibility to the Proteograph by focusing our resources on our commercial reach while preserving our balance sheet," said Omid Farokhzad, Chair and CEO of Seer. "Following the successful launch of STAC in the US, we are excited to announce we are expanding into Europe providing end-to-end services from sample to data for researchers across the region. We remain incredibly bullish on the potential of our technology to transform our understanding of the proteome."
“尽管本季度持续面临阻力，但我们仍致力于减少差异化技术商业采用的障碍。我们正在采取一切行动，将资源集中在商业范围上，同时保持资产负债表，从而增加Proteograph的可访问性。” Seer董事长兼首席执行官奥米德·法罗赫扎德说。“继在美国成功推出STAC之后，我们很高兴地宣布，我们将扩展到欧洲，为该地区的研究人员提供从样本到数据的端到端服务。我们仍然非常看好我们的技术有可能改变我们对蛋白质组的理解。”
First Quarter 2024 Financial Results
2024 年第一季度财务业绩
Revenue was $3.1 million for the first quarter of 2024, a 24% decrease from $4.1 million for the corresponding prior year period, primarily due to a decrease in product and related party revenue. Product revenue for the first quarter of 2024 was $2.5 million, including $828 thousand of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was $534 thousand for the first quarter of 2024, including $126 thousand of related party revenue, and primarily consisted of revenue related to the STAC program. Grant and other revenue was $36 thousand for the first quarter of 2024.
2024年第一季度的收入为310万美元，较上年同期的410万美元下降了24％，这主要是由于产品和关联方收入的减少。2024 年第一季度的产品收入为 250 万美元，包括 82.8 万美元的关联方收入，包括 SP100 仪器和消耗品套件的销售。2024年第一季度的服务收入为53.4万美元，其中包括12.6万美元的关联方收入，主要包括与STAC计划相关的收入。2024年第一季度的拨款和其他收入为36,000美元。
Gross profit, inclusive of grant and other revenue, was $1.4 million and gross margin was 44% for the first quarter of 2024.
2024年第一季度，包括补助金和其他收入在内的毛利为140万美元，毛利率为44％。
Operating expenses were $26.6 million for the first quarter of 2024, including $7.6 million of stock-based compensation, a decrease of 10% compared to $29.5 million for the corresponding prior year period, including $8.7 million of stock-based compensation. The decrease in operating expenses was primarily driven by a decrease in employee and stock-based compensation expenses and a decrease in laboratory expenses.
2024年第一季度的运营支出为2660万美元，其中包括760万美元的股票薪酬，与去年同期的2950万美元相比下降了10％，其中包括870万美元的股票薪酬。运营费用的减少主要是由员工和股票薪酬支出的减少以及实验室开支的减少所推动的。
Net loss was $20.7 million for the first quarter of 2024, as compared to $24.0 million for the corresponding prior year period.
2024年第一季度的净亏损为2,070万美元，而去年同期为2400万美元。
Cash, cash equivalents and investments were $359.2 million as of March 31, 2024.
截至2024年3月31日，现金、现金等价物和投资为3.592亿美元。
Seer announced today that its board of directors authorized an open-market share repurchase program of up to $25 million, which we expect will be effective upon the opening of Seer's trading window. Under the repurchase program, shares may be repurchased from time to time in open market transactions at prevailing market prices.
SEER今天宣布，其董事会批准了一项高达2500万美元的公开市场股票回购计划，我们预计该计划将在Seer交易窗口开放后生效。根据回购计划，可以不时以现行市场价格在公开市场交易中回购股票。
2024 Guidance
2024 年指导方针
Seer now expects full year 2024 revenue to be in the range of $16 million to $18 million, which is in line with full year 2023 revenue.
Seer现在预计，2024年全年收入将在1,600万美元至1,800万美元之间，与2023年全年收入持平。
Webcast Information
网络直播信息
Seer will host a conference call to discuss the first quarter 2024 financial results on Wednesday, May 8, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
Seer将于太平洋时间2024年5月8日星期三下午 1:30 /美国东部时间下午 4:30 主持电话会议，讨论2024年第一季度的财务业绩。电话会议的网络直播可在以下地址观看 https://investor.seer.bio。网络直播将在活动结束后至少 90 天内存档并可供重播。
About Seer
关于先知
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Seer 是一家生命科学公司，开发变革性产品，为蛋白质组打开了新的门户。Seer的Proteograph Product Suite是一种集成解决方案，包括专有的工程纳米颗粒、消耗品、自动化仪器和软件，可在短短几个小时内大规模进行深入、无偏见的蛋白质组学分析。Seer 设计的 Proteograph 工作流程既高效又易于使用，利用广泛采用的实验室仪器提供几乎任何实验室都可以采用的分散式解决方案。Seer 的 Proteograph 产品套件仅用于研究用途，不适用于诊断程序。欲了解更多信息，请访问 www.seer.bio。
Forward Looking Statements
前瞻性陈述
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer's expectations for future results of operations and its financial position, business strategy, customer publications and adoption and outlook for fiscal year 2024. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission (SEC) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新闻稿包含经修订的1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。此类前瞻性陈述基于Seer的信念和假设以及截至本新闻稿发布之日其目前获得的信息。前瞻性陈述可能涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致Seer的实际业绩、业绩或成就与前瞻性陈述所表达或暗示的业绩、业绩或成就存在重大差异。这些声明包括但不限于有关Seer对未来经营业绩的预期及其财务状况、业务战略、客户出版物以及2024财年的采用和展望的声明。Seer向美国证券交易委员会（SEC）提交的文件以及西尔随后不时向美国证券交易委员会提交的其他文件中对这些风险和其他风险进行了更全面的描述。除非法律要求，否则Seer没有义务更新此类声明以反映在声明发表之日后发生的事件或存在的情况。
Investor Contact:
Carrie Mendivil
investor@seer.bio
投资者联系人：
Carrie Mendivil
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio
媒体联系人：
帕特里克·施密特
pr@seer.bio
|
Seer, Inc. | |||||||
|
Condensed Consolidated Statements of Operations and Comprehensive Loss | |||||||
|
(Unaudited) | |||||||
|
(in thousands, except share and per share amounts) | |||||||
| Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Revenue: | |||||||
| Product | $ | 1,668 | $ | 2,343 | |||
| Service | 408 | 69 | |||||
| Related party | 954 | 1,306 | |||||
| Grant and other | 36 | 335 | |||||
| Total revenue | 3,066 | 4,053 | |||||
| Cost of revenue: | |||||||
| Product | 991 | 1,436 | |||||
| Service | 269 | 7 | |||||
| Related party | 312 | 478 | |||||
| Grant and other | 133 | 64 | |||||
| Total cost of revenue | 1,705 | 1,985 | |||||
| Gross profit | 1,361 | 2,068 | |||||
| Operating expenses: | |||||||
| Research and development | 12,265 | 14,474 | |||||
| Selling, general and administrative | 14,288 | 15,039 | |||||
| Total operating expenses | 26,553 | 29,513 | |||||
| Loss from operations | (25,192) | (27,445) | |||||
| Other income (expense): | |||||||
| Interest income | 4,586 | 3,717 | |||||
| Other expense | (73) | (231) | |||||
| Total other income | 4,513 | 3,486 | |||||
| Net loss | $ | (20,679) | $ | (23,959) | |||
| Other comprehensive gain (loss): | |||||||
| Unrealized gain (loss) on available-for-sale securities | (329) | 1,158 | |||||
| Comprehensive loss | $ | (21,008) | $ | (22,801) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.32) | $ | (0.38) | |||
| Weighted-average common shares outstanding, basic and diluted | 64,586,056 | 63,543,094 | |||||
| Seer, Inc. | |||||||
| 简明合并运营报表和综合亏损报表 | |||||||
| （未经审计） | |||||||
|
（以千计，股票和每股金额除外） | |||||||
| 截至3月31日的三个月 | |||||||
| 2024 | 2023 | ||||||
| 收入： | |||||||
| 产品 | $ | 1,668 | $ | 2,343 | |||
| 服务 | 408 | 69 | |||||
| 关联方 | 954 | 1,306 | |||||
| 格兰特等 | 36 | 335 | |||||
| 总收入 | 3,066 | 4,053 | |||||
| 收入成本： | |||||||
| 产品 | 991 | 1,436 | |||||
| 服务 | 269 | 7 | |||||
| 关联方 | 312 | 478 | |||||
| 格兰特等 | 133 | 64 | |||||
| 总收入成本 | 1,705 | 1,985 | |||||
| 毛利 | 1,361 | 2,068 | |||||
| 运营费用： | |||||||
| 研究和开发 | 12,265 | 14,474 | |||||
| 销售、一般和管理 | 14,288 | 15,039 | |||||
| 运营费用总额 | 26,553 | 29,513 | |||||
| 运营损失 | (25,192) | (27,445) | |||||
| 其他收入（支出）： | |||||||
| 利息收入 | 4,586 | 3,717 | |||||
| 其他费用 | (73) | (231) | |||||
| 其他收入总额 | 4,513 | 3,486 | |||||
| 净亏损 | $ | (20,679) | $ | (23,959) | |||
| 其他综合收益（亏损）： | |||||||
| 可供出售证券的未实现收益（亏损） | (329) | 1,158 | |||||
| 综合损失 | $ | (21,008) | $ | (22,801) | |||
| 归属于普通股股东的每股净亏损，基本亏损和摊薄后 | $ | (0.32) | $ | (0.38) | |||
| 已发行普通股、基本股和摊薄后加权平均值 | 64,586,056 | 63,543,094 | |||||
|
Seer, Inc. | |||||||
|
Condensed Consolidated Balance Sheets | |||||||
|
(in thousands, except share and per share amounts) | |||||||
|
March 31, 2024 |
December 31, 2023 |
||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 54,398 | $ | 32,499 | |||
| Short-term investments | 254,152 | 283,725 | |||||
| Accounts receivable, net | 3,815 | 4,831 | |||||
| Related party receivables | 989 | 559 | |||||
| Other receivables | 1,346 | 1,326 | |||||
| Inventory | 5,809 | 4,491 | |||||
| Prepaid expenses and other current assets | 3,641 | 3,082 | |||||
| Total current assets | 324,150 | 330,513 | |||||
| Long-term investments | 50,642 | 56,858 | |||||
| Operating lease right-of-use assets | 24,571 | 25,177 | |||||
| Property and equipment, net | 21,175 | 22,193 | |||||
| Restricted cash | 524 | 524 | |||||
| Other assets | 900 | 1,004 | |||||
| Total assets | $ | 421,962 | $ | 436,269 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 2,564 | $ | 1,370 | |||
| Accrued expenses | 7,572 | 9,212 | |||||
| Deferred revenue | 269 | 206 | |||||
| Operating lease liabilities, current | 2,280 | 2,295 | |||||
| Other current liabilities | 145 | 139 | |||||
| Total current liabilities | 12,830 | 13,222 | |||||
| Operating lease liabilities, net of current portion | 25,404 | 25,964 | |||||
| Other noncurrent liabilities | 173 | 179 | |||||
| Total liabilities | 38,407 | 39,365 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of March 31, 2024 and December 31, 2023; zero shares issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — | |||||
| Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 60,891,711 and 60,253,707 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 1 | 1 | |||||
| Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 4,044,969 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — | |||||
| Additional paid-in capital | 710,527 | 702,868 | |||||
| Accumulated other comprehensive loss | (521) | (192) | |||||
| Accumulated deficit | (326,452) | (305,773) | |||||
| Total stockholders' equity | 383,555 | 396,904 | |||||
| Total liabilities and stockholders' equity | $ | 421,962 | $ | 436,269 | |||
| Seer, Inc. | |||||||
| 简明合并资产负债表 | |||||||
|
（以千计，股票和每股金额除外） | |||||||
| 3月31日 2024 |
十二月三十一日 2023 |
||||||
| （未经审计） | |||||||
| 资产 | |||||||
| 流动资产： | |||||||
| 现金和现金等价物 | $ | 54,398 | $ | 32,499 | |||
| 短期投资 | 254,152 | 283,725 | |||||
| 应收账款，净额 | 3,815 | 4,831 | |||||
| 关联方应收款 | 989 | 559 | |||||
| 其他应收账款 | 1,346 | 1,326 | |||||
| 库存 | 5,809 | 4,491 | |||||
| 预付费用和其他流动资产 | 3,641 | 3,082 | |||||
| 流动资产总额 | 324,150 | 330,513 | |||||
| 长期投资 | 50,642 | 56,858 | |||||
| 经营租赁使用权资产 | 24,571 | 25,177 | |||||
| 财产和设备，净额 | 21,175 | 22,193 | |||||
| 受限制的现金 | 524 | 524 | |||||
| 其他资产 | 900 | 1,004 | |||||
| 总资产 | $ | 421,962 | $ | 436,269 | |||
| 负债和股东权益 | |||||||
| 流动负债： | |||||||
| 应付账款 | $ | 2,564 | $ | 1,370 | |||
| 应计费用 | 7,572 | 9,212 | |||||
| 递延收入 | 269 | 206 | |||||
| 经营租赁负债，当前 | 2,280 | 2,295 | |||||
| 其他流动负债 | 145 | 139 | |||||
| 流动负债总额 | 12,830 | 13,222 | |||||
| 经营租赁负债，扣除流动部分 | 25,404 | 25,964 | |||||
| 其他非流动负债 | 173 | 179 | |||||
| 负债总额 | 38,407 | 39,365 | |||||
| 承付款和意外开支 | |||||||
| 股东权益： | |||||||
| 优先股，面值0.00001美元；截至2024年3月31日和2023年12月31日已获授权的500万股；截至2024年3月31日和2023年12月31日已发行和流通的股票为零 | — | — | |||||
| A类普通股，面值0.00001美元；截至2024年3月31日和2023年12月31日已授权94,000,000股；截至2024年3月31日和2023年12月31日分别已发行和流通的60,891,711股和60,253,707股股票 | 1 | 1 | |||||
| B类普通股，面值0.00001美元；截至2024年3月31日和2023年12月31日已授权6,000,000股；截至2024年3月31日和2023年12月31日已发行和流通的4,044,969股股票 | — | — | |||||
| 额外的实收资本 | 710,527 | 702,868 | |||||
| 累计其他综合亏损 | (521) | (192) | |||||
| 累计赤字 | (326,452) | (305,773) | |||||
| 股东权益总额 | 383,555 | 396,904 | |||||
| 负债和股东权益总额 | $ | 421,962 | $ | 436,269 | |||
译文内容由第三方软件翻译。